Argipressin acetate (Embesin®)

Assessment Status Rapid Review Complete
Drug Argipressin acetate
Brand Embesin®
Indication For the treatment of catecholamine refractory hypotension following septic shock in patients older than 18 years. A catecholamine refractory hypotension is present if the mean arterial blood pressure cannot be stabilised to target despite adequate volume substitution and application of catecholamines.
Assessment Process
Rapid review commissioned 16/09/2019
Rapid review completed 11/10/2019
Rapid review outcome A full HTA is not recommended. The NCPE recommends that argipressin acetate (Embesin®) not be considered for reimbursement at the submitted price*.

The HSE has approved reimbursement following confidential price negotiations, March 2020.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.